Recent Analysts’ Ratings Changes for Bausch + Lomb (BLCO)

Bausch + Lomb (NYSE: BLCO) has recently received a number of price target changes and ratings updates:

• 12/12/2024 – Bausch + Lomb had its “underperform” rating reaffirmed by analysts at Bank of America Co.. They now have a $18.00 price target on the stock.
• 12/12/2024 – Bausch + Lomb had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
• 12/11/2024 – Bausch + Lomb was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $22.00 price target on the stock, down previously from $24.00.
• 12/2/2024 – Bausch + Lomb was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $19.00 price target on the stock.
• 10/31/2024 – Bausch + Lomb had its price target raised by analysts at Wells Fargo & Company from $23.00 to $26.00. They now have an “overweight” rating on the stock.
• 10/31/2024 – Bausch + Lomb had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 10/31/2024 – Bausch + Lomb had its price target raised by analysts at Citigroup Inc. from $20.00 to $24.00. They now have a “buy” rating on the stock.
• 10/31/2024 – Bausch + Lomb had its price target raised by analysts at HC Wainwright from $22.00 to $23.00. They now have a “buy” rating on the stock.
• 10/22/2024 – Bausch + Lomb had its price target raised by analysts at Royal Bank of Canada from $20.00 to $23.00. They now have an “outperform” rating on the stock.

Bausch + Lomb Stock Down 0.3 %

Shares of BLCO traded down $0.05 during mid-day trading on Monday, reaching $18.55. The company’s stock had a trading volume of 447,619 shares, compared to its average volume of 561,534. The company has a market cap of $6.53 billion, a price-to-earnings ratio of -17.67, a price-to-earnings-growth ratio of 1.74 and a beta of 0.43. The business has a fifty day moving average of $19.87 and a 200 day moving average of $17.53. The company has a quick ratio of 0.95, a current ratio of 1.57 and a debt-to-equity ratio of 0.69. Bausch + Lomb Co. has a 1 year low of $13.16 and a 1 year high of $21.69.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.16 by $0.01. The business had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The firm’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same period last year, the company posted $0.22 earnings per share. As a group, analysts forecast that Bausch + Lomb Co. will post 0.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bausch + Lomb

Large investors have recently made changes to their positions in the company. Blue Trust Inc. lifted its position in shares of Bausch + Lomb by 14,052.2% during the second quarter. Blue Trust Inc. now owns 3,255 shares of the company’s stock worth $47,000 after purchasing an additional 3,232 shares in the last quarter. Squarepoint Ops LLC bought a new position in Bausch + Lomb in the 2nd quarter worth approximately $173,000. Polar Asset Management Partners Inc. acquired a new position in Bausch + Lomb during the 3rd quarter worth $289,000. Gordian Capital Singapore Pte Ltd bought a new position in Bausch + Lomb in the 3rd quarter valued at $289,000. Finally, Verition Fund Management LLC acquired a new stake in shares of Bausch + Lomb in the 3rd quarter valued at $302,000. Institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.